title: Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
abstract: Cytopenia after high-dose chemotherapy and autologous stem cell reinfusion is a major cause of morbidity. Ex vivo cultured expansion and differentiation of CD34+ peripheral blood progenitor cells (PBPC) to neutrophil precursors may shorten the neutropenic period further. We explored the use of these ex vivo cultured PBPCs in nine patients with metastatic breast cancer. All underwent PBPC mobilization with cyclophosphamide, VP-16, and G-CSF. Subsequently, they underwent four to five apheresis procedures. One apheresis product from each patient was prepared using the Isolex 300 Magnetic Cell Separation System (Baxter Immunotherapy, Irvine, CA) to obtain CD34+ cells. These cells were then cultured in gas permeable bags containing serum-free X-VIVO 10 (BioWhittaker, Walkersville, MD) medium supplemented with 1% human serum albumin and 100 ng/mL PIXY321. At day 12 of culture the mean fold expansion was 26x with a range of 6 to 64x. One patient's cells did not expand because of a technical difficulty. The final cell product contained an average of 29.3% CD15+ neutrophil precursors with a range of 18.5% to 48.1%. The patients underwent high-dose chemotherapy with cyclophosphamide, carboplatin, and thiotepa. On day 0, the cryopreserved PBPCs were reinfused and on day +1 the 12-day cultured cells were washed, resuspended, and reinfused into eight of nine patients. One patient was not infused with cultured cells. The mean number of cultured cells reinfused was 44.6 x 10(6) cells/kg with a range of 0.8 to 156.6 x 10(6) cells/kg. No toxicity was observed after reinfusion. The eight patients have recovered absolute neutrophil counts > 500/microL on a median of 8 days (range 8 to 10 days); the median platelet transfusion independence occurred on day 10 (range 8 to 12 days) and platelet counts > 50,000/microL were achieved by day 12 (range 9 to 14) for the seven patients whose platelet counts could be determined. Expanded CD34+ selected PBPC can be obtained and safely reinfused into patients.
authors.affiliation: Department of Medicine, University of Chicago Medical Center, IL, USA.
authors.forename: S F
authors.initials: SF
authors.lastname: Williams
authors.forename: W J
authors.initials: WJ
authors.lastname: Lee
authors.forename: J G
authors.initials: JG
authors.lastname: Bender
authors.forename: T
authors.initials: T
authors.lastname: Zimmerman
authors.forename: P
authors.initials: P
authors.lastname: Swinney
authors.forename: M
authors.initials: M
authors.lastname: Blake
authors.forename: J
authors.initials: J
authors.lastname: Carreon
authors.forename: M
authors.initials: M
authors.lastname: Schilling
authors.forename: S
authors.initials: S
authors.lastname: Smith
authors.forename: D E
authors.initials: DE
authors.lastname: Williams
authors.forename: F
authors.initials: F
authors.lastname: Oldham
authors.forename: D
authors.initials: D
authors.lastname: Van Epps
mesh_terms: D000328:Adult; D018952:Antigens, CD34; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018929:Cell Culture Techniques / Q000295:instrumentation / Q000379:methods*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003470:Culture Media; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000494:pharmacology*; D005240:Feasibility Studies; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D018189:Immunomagnetic Separation; D007937:Leukapheresis; D016256:Lewis X Antigen; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control* / Q000628:therapy; D013629:Tamoxifen / Q000008:administration & dosage; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control* / Q000628:therapy
chemical_list: D018952:Antigens, CD34; D003470:Culture Media; D016256:Lewis X Antigen; D013629:Tamoxifen; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D013852:Thiotepa; D016190:Carboplatin; D008558:Melphalan